Hiroki Sano

Hiroki Sano

Auto-generated profile, based on publicly available information

Hiroki Sano

Department of Ophthalmology, Tokushima Red Cross Hospital, Komatsushima, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
HSHiroki Sano
Hiroki Sano
RYRyoji Yanai
Ryoji Yanai
YMYoshinori Mitamura
Yoshinori Mitamura
BACKGROUND Branch retinal vein occlusion (BRVO) is a common cause of vision loss in older adults, and cystoid macular edema (CME) is its most frequent vision-threatening complication. Depending on severity, vitreomacular traction (VMT) is typically managed with observation or surgery. When CME develops during observation (e.g., in BRVO), the therapeutic approach becomes more complex. Anti-vascular endothelial growth factor (VEGF) therapy is a standard treatment for CME secondary to BRVO. Although full-thickness macular hole (FTMH) formation is rare, it has been reported in eyes with preexisting VMT, suggesting a contributory role for tractional forces. CASE REPORT A 72-year-old woman under observation for VMT developed BRVO with CME. Baseline optical coherence tomography revealed VMT, an epiretinal membrane, a lamellar macular hole, and a vertical hyperreflective line at the fovea resembling the "foveal crack sign". The patient received an intravitreal faricimab injection to achieve rapid edema resolution with fewer injections. CME improved; however, an FTMH subsequently developed, accompanied by a decline in best-corrected visual acuity to 20/33. The patient then underwent combined vitrectomy and cataract surgery, which achieved successful hole closure. CME recurred postoperatively but responded well to a second faricimab injection, resulting in visual recovery to 20/22. CONCLUSIONS FTMH may develop after anti-VEGF therapy in eyes with preexisting VMT. This appears to be the first reported case following faricimab treatment for BRVO-associated CME, underscoring the need for careful pretreatment evaluation of the vitreoretinal interface and awareness of potential tractional complications. Individualized treatment strategies may help reduce such risks and improve outcomes.

24 October 2021 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
HSHiroki Sano
Hiroki Sano
HSHiroki Sano
Hiroki Sano
MNMasanori Niki
Masanori Niki
KSKentaro Semba
Kentaro Semba
FMFumiko Murao
Fumiko Murao
YMYoshinori Mitamura
Yoshinori Mitamura
Aims/Introduction Inhibition of peroxisome proliferator-activated receptor gamma (PPARγ) phosphorylation mediated by cyclin-dependent kinase 5 (Cdk5) is one of the main mechanisms of action of antidiabetic drugs. In this study, we analyzed the ocular expression and activation of Cdk5 in patients with proliferative diabetic retinopathy (PDR). Materials and Methods The concentrations of PPARγ, Cdk5, and its activating subunit (p35) were determined in the vitreous body of 24 PDR and 63 control eyes by enzyme-linked immunosorbent assay. In addition, the mRNA and protein expression levels of PPARγ, Cdk5, and p35 were measured in proliferative neovascular membranes from seven PDR eyes and non-neovascular epiretinal membranes from five control eyes by quantitative real-time polymerase chain reaction and immunohistochemical analysis. Results PPARγ, Cdk5, and p35 concentrations in the vitreous body were significantly higher in the PDR group compared with the control group. There was also a positive significant correlation of Cdk5 with PPARγ and p35 in the PDR group. Furthermore, the mRNA expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes were significantly higher in the PDR group compared with the control group. Immunostaining revealed increased protein expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes in the PDR group compared with the control group. Conclusions Cdk5 activation is involved in PDR pathogenesis via PPARγ expression, and inhibition of Cdk5-mediated PPARγ phosphorylation may be a new therapeutic target for treatment of PDR.

8 October 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
HSHiroki Sano
Hiroki Sano
RYRyoji Yanai
Ryoji Yanai
YMYoshinori Mitamura
Yoshinori Mitamura

21 July 2026 in Ophthalmology Retina
Verified
Journal Article
Open access
HSHiroki Sano
Hiroki Sano
RYRyoji Yanai
Ryoji Yanai
HKHirotaka Kondo
Hirotaka Kondo
TMTakafumi Misaki
Takafumi Misaki
DNDaisuke Nagasato
Daisuke Nagasato
YMYoshinori Mitamura
Yoshinori Mitamura

29 April 2026 in American Journal of Case Reports
Verified
Journal Article
Open access
HSHiroki Sano
Hiroki Sano
RYRyoji Yanai
Ryoji Yanai
YMYoshinori Mitamura
Yoshinori Mitamura
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report - Article abstract #952247

12 September 2026 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
HSHiroki Sano
Hiroki Sano
RYRyoji Yanai
Ryoji Yanai
YHYuto Hayahara
Yuto Hayahara
YMYoshinori Mitamura
Yoshinori Mitamura